Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
Biological considerations suggest that renin-angiotensin system inhibitors might influence the severity COVID-19 Replace trial was a prospective, open-label trial done at 20 large referral hospitals in seven countries. 29% of participants in the continuation group and 28% in the discontinuation group had at least one adverse event. There was no difference in blood pressure, serum potassium, or creatinine during follow-up across the two groups. Renin–angiotensin system inhibitors can be safely co
